Free Trial

89bio (ETNB) Competitors

89bio logo
$7.94 +0.91 (+12.94%)
(As of 12/20/2024 05:31 PM ET)

ETNB vs. JANX, EWTX, XENE, MRUS, TWST, ACAD, MOR, SWTX, ZLAB, and VCEL

Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Merus (MRUS), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

89bio vs.

89bio (NASDAQ:ETNB) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.

In the previous week, 89bio had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for 89bio and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.23 beat 89bio's score of 0.57 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
89bio
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Janux Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89bio has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
89bioN/A -59.58% -52.21%
Janux Therapeutics -463.91%-10.47%-9.86%

89bio presently has a consensus target price of $30.33, suggesting a potential upside of 282.03%. Janux Therapeutics has a consensus target price of $89.90, suggesting a potential upside of 58.19%. Given 89bio's higher possible upside, research analysts clearly believe 89bio is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89bio
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.86
Janux Therapeutics
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

75.4% of Janux Therapeutics shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

89bio has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500.

Janux Therapeutics has higher revenue and earnings than 89bio. Janux Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A-$142.19M-$2.91-2.73
Janux Therapeutics$13.05M228.57-$58.29M-$1.17-48.57

89bio received 68 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.18% of users gave Janux Therapeutics an outperform vote while only 64.67% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
89bioOutperform Votes
108
64.67%
Underperform Votes
59
35.33%
Janux TherapeuticsOutperform Votes
40
70.18%
Underperform Votes
17
29.82%

Summary

Janux Therapeutics beats 89bio on 12 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ETNB vs. The Competition

Metric89bioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$842.64M$6.57B$5.13B$9.08B
Dividend YieldN/A2.99%4.93%4.22%
P/E Ratio-2.7310.5589.5817.18
Price / SalesN/A195.351,115.01116.87
Price / CashN/A57.1642.8237.86
Price / Book1.385.104.804.78
Net Income-$142.19M$151.51M$120.04M$225.60M
7 Day Performance3.25%-2.12%-1.91%-1.23%
1 Month Performance-5.25%-3.10%11.48%3.36%
1 Year Performance-25.93%11.54%30.59%16.59%

89bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ETNB
89bio
1.7833 of 5 stars
$7.94
+12.9%
$30.33
+282.0%
-22.4%$842.64MN/A-2.7340News Coverage
Positive News
High Trading Volume
JANX
Janux Therapeutics
3.6708 of 5 stars
$61.98
+1.4%
$89.90
+45.0%
+496.3%$3.25B$13.05M-52.2330Positive News
EWTX
Edgewise Therapeutics
2.7263 of 5 stars
$33.79
+22.3%
$42.33
+25.3%
+261.7%$3.20BN/A-22.8560Analyst Forecast
Analyst Revision
High Trading Volume
XENE
Xenon Pharmaceuticals
2.7945 of 5 stars
$41.02
+2.4%
$56.90
+38.7%
-5.8%$3.13B$9.43M-14.20251Insider Trade
MRUS
Merus
2.8078 of 5 stars
$43.00
+0.4%
$85.64
+99.2%
+61.7%$2.94B$35.93M-10.8437
TWST
Twist Bioscience
2.5561 of 5 stars
$48.66
+2.4%
$51.90
+6.7%
+36.7%$2.89B$312.97M-13.19990
ACAD
ACADIA Pharmaceuticals
3.8468 of 5 stars
$17.32
+0.3%
$25.60
+47.8%
-41.9%$2.88B$726.44M22.13510
MOR
MorphoSys
0.127 of 5 stars
$18.96
+2.4%
$14.33
-24.4%
N/A$2.86B$238.28M-5.45730News Coverage
SWTX
SpringWorks Therapeutics
2.0114 of 5 stars
$37.91
-1.0%
$69.50
+83.3%
+11.3%$2.82B$5.45M-9.87305
ZLAB
Zai Lab
1.7095 of 5 stars
$25.94
-1.5%
$55.00
+112.0%
-7.4%$2.82B$355.75M-9.512,175
VCEL
Vericel
1.4381 of 5 stars
$56.98
-0.9%
$59.71
+4.8%
+66.0%$2.81B$226.84M957.83300Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ETNB) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners